Rivaroxaban was shown to be more effective than enoxaparin in preventing major venous thromboembolic events after nonmajor orthopedic surgery of the lower limbs, according to late-breaking trial results presented Sunday at the American College of Cardiology Scientific Sessions 2020 virtual conference.